
Please try another search
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company focuses on degrader-antibody conjugate that combine antibody-drug conjugate with targeted protein degradation technology. Its lead product candidate is ORM-1153, a GSPT1 protein degrader that targets hematologic malignancies. The company was founded in 2016 and is based in Daejeon, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Peter U. Park | - | 2025 | Director & Member of Advisory Board |
Martin Intae Jeong | - | 2023 | CFO & Director |
Ki Chul Cho | 47 | 2025 | Member of Advisory Board |
Sung-Joo Lee | - | - | Founder, CEO & Director |
Jinwoo Jo | - | - | Director |
Maria Koehler | 68 | 2022 | Member of Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review